UBS Reaffirms Buy on BridgeBio (BBIO) With Optimism Around Attruby Launch

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks among the best biotech stocks to buy. UBS reaffirmed its Buy rating for BridgeBio Pharma, Inc. (NASDAQ:BBIO) on September 22, citing the company’s Attruby medication launch. The firm is optimistic about Attruby’s launch trajectory, citing a high number of new patient diagnoses.

According to UBS, Attruby has the potential to become a major product that generates over $4 billion in long-term revenue, which is bolstered by growing data showing how it differs from rival medication tafamidis.

In addition to highlighting BridgeBio’s pipeline beyond Attruby as “underappreciated,” the firm also pointed out that three Phase 3 readouts are expected within the next six months, which together might match Attruby’s revenue potential.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biopharmaceutical company that was founded to discover, develop, evaluate, and market cutting-edge medication to cure genetic illnesses.

While we acknowledge the potential of BBIO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BBIO and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.